Navigation Links
LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit
Date:6/4/2009

mportant in cancer biology, including genes that regulate angiogenesis, cell metabolism, cell proliferation, cell death (apoptosis) and cell invasion. HIF-1 alpha protein is low in normal cells, but reaches high intracellular concentrations in a variety of cancers and is strongly correlated with poor prognosis and resistance to therapy. Enzon is currently conducting two Phase I studies, evaluating the HIF-1 alpha antagonist in different dosing schedules. The HIF-1 alpha inhibitor is licensed from Santaris Pharma A/S.

The collaboration between Santaris Pharma and Enzon Pharmaceuticals started in 2006 and by 2008 Santaris Pharma had delivered eight LNA based cancer drugs to Enzon Pharmaceuticals of which EZN-2968 was the first. The development of the remaining seven compounds is in progress. Moving forward Enzon is committed to the late stage pre-clinical development of these lead candidates. Santaris Pharma holds the European commercial rights to all the jointly developed cancer compounds.

Santaris Pharma (founded in 2003) is a privately held biopharmaceutical company developing new classes of RNA medicines targeting disease-related mRNAs and miRNAs based on its proprietary LNA Drug Platform. The Company's own research and development activities focus on microRNAs, infectious diseases and metabolic disorders. In addition, Santaris Pharma is leveraging its highly effective and efficient Drug Discovery Engine to generate lead LNA drug candidates against a broad array of disease targets selected by strategic partners. The Company and its corporate partners currently have four compounds in clinical development and a full pipeline in late preclinical development.

    For further information, please contact
    Randi Krogsgaard, Director, Corporate Communications
    Direct phone +45-4517-9879
    Cell: +45-2048-8384
    E-mail: rmk@santaris.com

   
SOURCE Santaris Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
2. LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs
3. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
4. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
5. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
6. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
7. AlphaVax Announces New CMV Advisory Board
8. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
9. Maxygen Announces Hold on MAXY-alpha Development Program
10. VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
11. Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... (PRWEB) May 21, 2015 Patent Offering, ... method for diagnostic or therapeutic imaging within a body ... uses an endoscope having a low cost, single-use disposable ... filing date was October 18, 2013 and the patent ... technology enables the physician to customize the lighting and ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Veolia’s ... an exclusive North American distribution agreement with VWR ... system. , With more than 160 years of ... and services for laboratory and production facilities, has ... excellence and differentiated services to enable science. ...
(Date:5/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) ... Therapy Market Outlook 2020 " report to their ... and regenerative medicine is expected to have huge marketing ... help in the growth of deregulated organs. Several therapeutic ... unable to form new tissue or sometimes organ transplant ...
(Date:5/20/2015)... YORK , May 20, 2015  Marc ... a leadership gift of $100 million from The ... create a new laboratory building that will be ... extension. The Marie-Josée and Henry R. Kravis Research ... the FDR Drive, spanning approximately three city blocks ...
Breaking Biology Technology:IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4
... Efficient Cellular Fractionation for RNA , ... Ambion's Protein and RNA Isolation System, , ... total RNA and native protein from the same ... tissues that are either fresh, , ...
... Because of its apparent specificity, , ... accelerating the functional characterization of , ... and basic research efforts. To ensure ... data, however, proper experimental design and controls are , ...
... mir ... Sensitive -- Detect miRNA or siRNA in as little as 10 ng ... need to optimize hybridization , or washing conditions , ... to membrane for hybridization , ...
Cached Biology Technology:Efficient Cellular Fractionation for RNA , and Protein Isolation 2Efficient Cellular Fractionation for RNA , and Protein Isolation 3Efficient Cellular Fractionation for RNA , and Protein Isolation 4Efficient Cellular Fractionation for RNA , and Protein Isolation 5Efficient Cellular Fractionation for RNA , and Protein Isolation 6Efficient Cellular Fractionation for RNA , and Protein Isolation 7Designing Controls for siRNA , Experiments 2Designing Controls for siRNA , Experiments 3Designing Controls for siRNA , Experiments 4Designing Controls for siRNA , Experiments 5Detecting Attomole Amounts of Small RNA 2Detecting Attomole Amounts of Small RNA 3
(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... is available in Spanish . Cancer ... only these adaptative changes give higher proliferative capacity to ... to chemotherapeutic agents. The research group led by Dr. ... Barcelona of the CSIC (IIBB-CSIC), a centre linked to ...
... its tell-tale memory and physical coordination impairments after affected ... that creates these impairments is thought to be partly ... The current study now shows that this inflammatory response ... it inflicts brain damage. The British group ...
... of chemistry and T. Pipes endowed chair in micro ... a Louisiana Tech doctoral candidate in biomedical engineering feature ... issue of Pharma Focus Asia, one of ... the world. "This is the largest Asian pharmacological ...
Cached Biology News:Mitochondrial cholesterol makes response to chemotherapy difficult in hepatic cancer 2Louisiana Tech researchers feature drug reformulation in prestigious journal 2Louisiana Tech researchers feature drug reformulation in prestigious journal 3
Recombinant Equine IL-6...
dithiothreitol (DTT) Reactive Dyes and Chemicals Thiol-Reactive Dyes, Haptens and Quenchers Reducing Agents...
GRADIENT MAKER, 30 ML, 1 EA. Category: Protein Vertical Instruments....
Recombinant Rat Leptin, CF...
Biology Products: